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Abstract
Wound healing in diabetes is frequently impaired and its treatment remains a challenge. Hyperbaric oxygen therapy (HBOT)
receives a wide attendance and is often used as a last resort treatment option, however, its effectiveness for many
conditions is unproven. We tested the effect of HBOT on healing of diabetic ulcers in an animal experimental setting.
Experimental diabetes was induced by intraperitoneal injection of streptozotocin. Four weeks after diabetes induction, rats
were ulcerated by clamping a pair of magnet disks on the dorsal skin for 16 h. After magnet removal, the animals received
HBOT, daily on weekdays, for 4 weeks. To examine the effect of HBOT on diabetes impaired wound healing, the degree of
wound tissue perfusion, inflammation, angiogenesis, and tissue breaking strength were evaluated. HBOT effects on the
degree of inflammation and number of blood vessels could not be observed. HBOT improved the tissue breaking strength
of the wound, however, this did not reach statistical significance. Twenty hours after ending the HBOT, a significantly
improved oxygen saturation of the hemoglobin at the venous end of the capillaries and the quantity of hemoglobin in the
micro-blood vessels was measured.
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Introduction
Wound healing failure in diabetes represents a significant
clinical problem with an predicted further increase in patient
numbers and impact [1]. The pathophysiology of diabetic ulcers is
largely due to hyperglycemia and implicates blood vessel
abnormalities and damage, particularly in the microvasculature,
that may lead to the low oxygen tension causing tissue hypoxia and
ischemia [2]. In patients with diabetes, this underlying pathology is
considered to affect foot ulcer chronicity. The impaired healing
observed in diabetic patients and diabetic animal models, overlap
in many aspects, such as a disturbed inflammatory response, an
abnormal microvasculature and an aberrant collagen synthesis
and ripening [3].
The medical use of hyperbaric oxygen (hyperbaric oxygen
therapy: HBOT) is the use of pure oxygen at an increased
pressure. Frequently used is a treatment regimen where the patient
breathes 100% oxygen at a pressure of 2.4 atmospheres absolute
(ATA) for 1.5–2 hours, on a daily basis during weekdays, for 6 to 8
weeks. During treatment, the arterial oxygen tension is described
to rise over 2000 mmHg, and levels of 200 to 400 mmHg occur in
tissues in part due to an increased plasma oxygen content and
microvascular blood flow [4]. In a The Cochrane Collaboration
Review on Hyperbaric oxygen therapy for chronic wounds,
Kranke et al (2012) concluded that HBOT may improve the
chance of healing of diabetes-related foot ulcers and may reduce
the number of major amputations in these patients [5]. Due to
obvious reasons, efficacy determination for the use of HBOT in
clinical studies does not allow the in depth laboratory analysis that
can be reached when using animal models.
Therefore, in this study, the effect of HBOT on improving
oxygenation of the wound bed was analysed in a preclinical setting
using a validated ischemia experimental wound model in
streptozotocin (STZ)-diabetic rats, with an approximately two-
fold delay in ulcer healing time [3].
Materials and Methods
Animals
WAG/RijHsd female rats (n = 24, 8 weeks old) were purchased
from Charles River (l’Arbresle, France). The rats were exposed to
a 12-hour light/dark cycle and fed with a standard laboratory diet
(Hope Farms, Woerden, The Netherlands) with food and water
available ad libitum. The rats were allowed to acclimatize to their
environment for one week prior to the procedure. The experi-
mental protocol was approved by the Animal Experiments
Committee(Permit Number EMC2585) under the national exper-
iments on animals act and adhered to the rules laid down in this
national law that serves the implementation of ‘‘Guidelines on the
protection of experimental animals’’ by the Council of Europe
(1986), Directive 86/609/EC.
Induction of diabetes
After overnight fasting, animals were given an intraperitoneal
injection of STZ (Sigma-Aldrich, St. Louis, MO) at a dose of
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60 mg/kg body weight in 0.05 mol/L sodium citrate buffer,
pH 4.5. Blood glucose concentration was monitored twice weekly
the first 3 weeks and weekly afterwards by a OneTouch
glucometer (LifeScan, Milpitas, CA) from tail vein blood. Glucose
levels of 33 mmol/L and above were displayed by the apparatus as
33 mmol/L. A prolonged diabetes status was defined as blood
glucose levels $20 mmol/L throughout the entire diabetes
induction period.
Ulceration model and HBOT
Four weeks after STZ injection, two rats returned to normal
glucose levels and were excluded from further experimentation.
Twenty two diabetic rats had a prolonged diabetic status and were
ulcerated by clamping a pair of magnet disks (15-mm in diameter)
on the dorsal skin for a single ischemic period of 16 h. This
procedure gave drop in perfusion during clamping to at least 40%
of the starting perfusion and a recovery perfusion of 60% and
resulted in 2 wounds per animal [3,6]. The rats received temgesic
0,05 mg/kg (Reckitt Benkiser Pharmaceuticals, Berkshire, UK)
during magnet clamping and three days post-operative. Immedi-
ately after magnet removal, rats were randomly allocated into two
groups to serve the two experimental end points (i.e., day 7, n= 6;
day 29, n = 16). The rats in each group were randomly assigned to
the HBOT or normoxia group. HBOT rats were given 100%
oxygen under a pressure of 2.4 ATA for 90 min. The control
group received normoxia at sea level pressure. During HBOT,
animals were single housed in cages [7]. Control rats were placed
next to the machine to experience analogous stress created by the
noise of the machinery and breathed normoxia at normal
pressure. The first HBOT was initiated approximately 30 min
after the magnet was removed and continued once a day from
Mondays through Fridays until the experimental end point was
reached and the animals were euthanized. For all experimental
outcome, observers were blinded to the treatment.
Macroscopic analysis
Body weight and blood glucose levels were measured and the
ulcers were photographed, all on a weekly basis.
Perfusion measurements
Oxygen supply in the microcirculation of the wound tissue was
measured at the wound edges using an O2C laser doppler flow
meter and tissue spectrometer (LEA Medizintechnik, Giessen,
Germany). Capillary-venous oxygen saturation of the hemoglobin
(SO2) was measured at the venous end of the capillaries, which
represents the lowest oxygen saturation of the tissue. The relative
amount of hemoglobin (rHB) represents the quantity of hemoglo-
bin in the micro-blood vessels and, therefore, reflects the density of
the blood vessels. In addition, the blood flow in the microcircu-
lation was determined [8]. Intra- and inter-operator variability
and measurement probe repositioning was secured and the
sensitivity of the measurement determined by measuring an
animal directly after HBOT. We could demonstrate high SO2
values that gradually lowered in time. The results of some of these
measurements can be found in Data S2.
Immunohistochemistry
At the experimental endpoint at day 7, the entire wound was
paraffin-embedded. At experimental endpoint at day 29, the
wound area was cut into two halves. One half was paraffin
embedded. The other half was used to measure the breaking
strength. Paraffin-embedded sections (5 mm), n= 6 per group and
time point, were deparaffinized and rehydrated. Antigen retrieval
was performed in Tris-EDTA buffer containing 0.1% trypsin
(Invitrogen, Carlsbad, CA). Endogenous peroxidase activity was
quenched by exposing to 0.1% hydrogen peroxide in PBS
containing 0.1% Tween 20 (PBST). After blocking with 4%
nonfat milk powder in PBST, the sections were incubated with
mouse anti-CD68 (1:100; AbD Serotec, Du¨sseldorf, Germany) and
goat anti-CD34 (1:200; DakoCytomation, Glostrup, Denmark),
respectively, followed by incubating with the corresponding
biotinylated secondary antibodies (DakoCytomation). The anti-
gen-antibody complex was detected by streptavidin-peroxidase
(DakoCytomation) and 3,39-diaminobenzidine (Sigma-Aldrich,
Zwijndrecht, the Netherlands).
Breaking strength measurements
At experimental day 29, the wound area was cut into two
halves. One half was paraffin embedded. The other half was used
to measure the breaking strength as described previously [9]. In
brief, the excised dorsal pelt which contained the ulcer, was cut
into two standardized dumbbell-shaped skin strips. One strip was
cut from the non-wounded skin surrounding the wound area and
the other strip was centered by the mid segment of the ulcer. The
strip was fixed perpendicularly between two clips of a tensiometer
(Testometric AX, M250-2.5KN, Testometric Company Ltd.,
Lancashire, UK) and subjected to a constant strain rate of
60 mm/min using a 10-kg force transducer. Breaking strength was
recorded as the maximum load (in Newton) measured before skin
failure. The ratio of ulcer breaking strength to that of surrounding
normal skin breaking strength was calculated for data analysis. In
control animals at experimental day 29, the breaking strength of
non-wounded skin was determined in 7 skin strips (1 strip per
animal). the breaking strength of wounded skin in 14 skin strips (1
strip per wound, 2 wounds per animal). In HBOT animals at
experimental day 29, the breaking strength of non-wounded skin
Table 1. Group data for blood glucose (mmol/L) for the control group and HBOT group.
blood glucose at: HBOT group control group
diabetes induction 5.360.2 6.560.4
wound induction 32.460.4 33.060
week 1 32.660.4 33.060
week 2 32.160.5 33.060
week 3 32.160.6 32.760.3
week 4 32.260.4 32.460.6
Data are presented as means 6 SEM. A glycometer reading of 33 represents tail vein glucose levels of 33 mmol/L and above.
doi:10.1371/journal.pone.0108533.t001
HBOT and Diabetes Impaired Wounds
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was determined in 9 skin strips (1 strip per animal). The breaking
strength of wounded skin in 18 skin strips (1 strip per wound, 2
wounds per animal).
Statistical analysis
Data are presented as means 6 SEM. Statistical calculations
were performed using IBM SPSS software, version 21 (Chicago,
IL). An independent samples Student’s t test was carried out to
compare results between groups. P-values #0.05 were considered
to indicate statistically significant differences.
Table 2. Group data for body weight (gram) for the control group and HBOT group.
Animal weight percentage at HBOT group control group
diabetes induction 14663 14062
wound induction 14062 13462
week 1 14462 13662
week 2 14362 14064
week 3 14163 13963
week 4 13962 13663
Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0108533.t002
Figure 1. Macroscopic images of control and HBOT wounds at post-wounding days 7 and 29.
doi:10.1371/journal.pone.0108533.g001
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Results
Diabetes induction
During the 3.5–4 week diabetes induction period, 22 STZ-
injected rats became consistently hyperglycemic, with glucose
levels .20 mmol/L during the entire experimental period, and
were included in this study. Two rats returned to normoglycemia
and were excluded from the experiment (Table 1).
Bodyweight changes
During the 3.5–4 weeks of diabetes induction, the biggest
individual weight loss observed was 15%. On a per group bases,
the biggest weight loss was 10% for animals in the control group
and 4% for animals in the HBOT group (statistically non
significant: NS). At the end of the diabetes induction period, all
animals increased weight and almost returned to their starting
weight 14062 gram versus 13462 gram: NS, for HBOT-group
and control-group animals, respectively). During the experimental
period, also no significant differences in animal weight were
observed between the control and HBOT group (Table 2).
Histological observations
Both at experimental days 7 and 29, no differences between the
control and HBOT group were observed in the macroscopic
observation of the wound area (Figure 1). Also in an overall
histological view of the wound (H&E stain) (Figure 2A–D) and in
the number of blood vessels (CD34 immunohistochemistry)
(Figure 2E–H) or macrophages (CD68 immunohistochemistry)
(Figure 2I, J) no obvious differences were observed.
Perfusion measurements
Approximately 20 hours after the last HBOT (or control) session
at experimental day 29, the capillary-venous oxygen saturation
(SO2), the relative amount of hemoglobin (rHB) and blood flow in
the microcirculation were determined in non-wounded (control)
skin and at the wound edge.
In control skin, a trend towards a reduced flow was found
(119.5615.2 versus 86.4611.4 artificial units (AU): p = 0.1, for
control and HBOT animals, respectively). This reduction in flow
reached significance in wound tissue (131.2618.0 versus 85.165.3
AU: p= 0.03, for control and HBOT animals, respectively)
(Figure 3). Oxygen saturation of the hemoglobin (SO2) at the
venous end of the capillaries was not significantly changed in
control skin, however, was significantly increased in HBOT
wound tissue (28.962.4% and 39.163.5%: p= 0.03, for control
and HBOT animals, respectively). Also the relative hemoglobin
(rHB), the quantity of hemoglobin in the micro-blood vessels, is
significantly increased in HBOT wound tissue (15.461.2 versus
22.461.5 AU: p= 0.001, for control and HBOT animals,
respectively) (Figure 3).
In order to compensate for possible animal to animal variation
in tissue architecture and vascular characteristics, we recalculated
the above wounded skin perfusion parameters as a percentage of
the skin perfusion of the normal skin in the respective animal. In
this case, flow in the microcirculation did not reach statistical
difference (1.0960.11 versus 1.1660.14: NS, for control and
HBOT animals, respectively) indicating that HBOT restricts
blood flow both in control and wounded skin. In contrast, oxygen
saturation of the hemoglobin at the venous end of the capillary
system (SO2:0.6460.08 versus 0.8760.07, p = 0.04, for control
and HBOT animals, respectively) and the quantity of hemoglobin
in the micro-blood vessels (rHB: 1.7560.18 versus 2.2560.11:
p = 0.03, for control and HBOT, respectively) where increased in
the HBOT group (Figure 4).
Figure 2. Histological staining of control and HBOT wounds at post-wounding days 7 and 29. A–D) H&E staining. E–H) CD34
immunohistochemistry. I+J) CD68 immunohistochemistry.
doi:10.1371/journal.pone.0108533.g002
Figure 3. The effect of HBOT on blood flow, oxygen saturation of the hemoglobin at the venous end of the capillaries (SO2), and
the quantity of hemoglobin in the micro-blood vessels (rHB). Effects were measured, in control skin and at the wound edge in control and
HBOT animals, approximately 20 hours after the last HBOT session. Data are presented as means 6 SEM. P-values indicate differences between the
respective control group and HBOT group. AU= artificial units.
doi:10.1371/journal.pone.0108533.g003
HBOT and Diabetes Impaired Wounds
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Skin breaking strength measurements
At the experimental endpoint at day 29, HBOT treatment
improved the mean breaking strength of unwounded skin by 27%,
compared to controls, however, this did not reach statistical
significance (36.2964.29N versus 46.1663.57N: p= 0.1, for
control and HBOT, respectively). Also the mean skin strength
ratio in HBOT-treated ulcers was improved by 19% but this
observation did not reach statistical significance (8.5160.70N
versus 10.1660.65N: p= 0.1, for control and HBOT, respectively)
(Figure 5).
Discussion
This study demonstrated effects of 4 weeks of HBOT on the skin
of diabetic animals. HBOT significantly improved oxygen
saturation and the quantity of hemoglobin in the micro blood
vessels in the wound area. HBOT also improved the tissue
breaking strength of the wounded and non-wounded skin of these
diabetic rats but this did not reach statistical significance.
In this STZ-diabetic rat model, glucose levels and animal
weights were stable during the entire diabetes induction and
experimental period. HBOT treatment did not influence this.
Figure 4. The effect of HBOT on blood flow, oxygen saturation of the hemoglobin at the venous end of the capillaries (SO2), and
the quantity of hemoglobin in the micro blood vessels (rHB). Effects were measured in control and HBOT animals, approximately 20 hours
after the last HBOT session, and expressed as a percentage of the values of non-wounded skin in the respective animal. Data are presented as means
6 SEM. P-values indicate differences between the respective control group and the HBOT group.
doi:10.1371/journal.pone.0108533.g004
Figure 5. Ratio of the skin breaking strength of normal skin and wounded skin in diabetic rats at day 29 post wounding. Data are
presented as means 6 SEM. P-values indicate differences between the control group and the HBOT group.
doi:10.1371/journal.pone.0108533.g005
HBOT and Diabetes Impaired Wounds
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e108533
HBOT animals displayed a significant reduction in blood flow in
the wound area. In contrast, oxygen saturation of the hemoglobin
at the venous end of the capillaries (SO2), and the quantity of
hemoglobin in the micro-vessels (rHB) both were significantly
increased in the wounded skin of HBOT treated animals. Since we
measured tissue perfusion 20 hours after the final HBOT
treatment, this reflects a lasting effect of HBOT in oxygenating
the wound area. Klemetti et al. also reported a lasting increase in
vascular capacity following HBOT [10]. In their rat mandible
bone defect model, increased Laser Doppler Flow values in the
wound were observed 14 days after the HBOT ended.
The mechanism of action of HBOT is considered to occur via
increasing the oxygen content of poorly vascularized areas. A
number of HBOT effects are described in literature some having
conflicting predictions on wound healing. Vasoconstriction is a
well described effect of HBOT [11], likely mediated by the
inactivation of nitric oxide through superoxide radicals [12]. We
also observed a HBOT reduced blood flow of which a negative
impact to wound healing can be envisioned. In contrast, a variety
of additional HBOT effects exist that likely have a positive result
on wound healing. We observed an increase in hemoglobin
oxygenation and perfusion. In addition, the administration of pure
oxygen at a raised pressure of 2.4 ATA, is thought to give oxygen
dissolved plasma levels that are sufficient for the tissue, even
without the support of HB-bound oxygen. This way, plasma
exvasation is considered to increase the oxygen content of lesser
vascularized areas [11], as in poorly vascularized wounds [13]. Fife
et al [14] demonstrated, in humans with diabetic lower extremity
wounds, the direct relationship between transcutaneous oxygen
tension (TcPO2) measurements during HBOT and healing
improvement of this treatment.
In addition to this direct effect on oxygen availability in tissue, it
is suggested that HBOT promotes angiogenesis during wound
healing via an increased availability of wound growth factors, of
which VEGF is most noted [15]. Sheikh et al. demonstrated
increased VEGF levels in wound fluid aspirates of surgical wounds
in rats that were treated with HBOT twice daily [16]. VEGF levels
returned to normal three days after ending HBOT. Increased
VEGF, and enhanced angiogenesis, mostly is described in reaction
to hypoxia conditions [17]. All together, these data may indicate
that increased VEGF levels arise as a response to deviation from
normoxia. Yuan et al. applied HBOT to in vitro aortic prepara-
tions and assayed the NO and VEGF production [18]. No direct
effect of HBOT on VEGF expression was noted. However, a mild
increase of VEGF, following HBOT, was observed when the
culture medium was supplemented with lactate to mimic the
poorly oxygenated wound conditions.
Although skin breaking strength (failure force) was improved by
about 20% in the HBOT animals, this observation did not
research statistical significance. This HBOT effect was observed in
wounded skin but also in normal (non-wounded) diabetic skin
revealing a general improvement of the skin perfusion by HBOT.
Compared to the skin of normal animals, diabetic skin has a
significantly reduced epidermal thickness and is less vascularized
(our unpublished findings). In a previous study, we reported on the
effects of a glycosaminoglycan mimic, OTR4120, on improving
diabetic wound repair [3]. Here, wound breaking strength was
increased 50% but limited to the wound area. The breaking
strength of the unwounded skin was not improved suggesting the
absence of prolonged matrix damage in this diabetes model.
However, the increase in skin breaking strength in wounded and
non-wounded skin of the HBOT group may reflect an improve-
ment in dermal architecture. However, in a histological analysis,
no evidence regarding alteration of the skin architecture or in the
number of blood vessels in the skin, could be observed in the
HBOT groups. Nevertheless, subtle differences in skin architecture
like collagen cross linking and/or differences in collagen organi-
zation may underlay this observation and may be below the
threshold of a histological observation.
When we compare our current findings on the speed of wound
healing, the superior oxygen saturation andquantity of haemoglobin
observed with HBOT, did not reveal striking differences when
compared toourprevious studywherewere tested theeffect ofmatrix
therapy on wound healing [3]. However, a disclaimer needs to be
made as, in the current study we followed wound healing for only 4
weeks in contrast to 12 weeks in the study of Tong [3].
An experimental limitation of our study is that we only could
measure oxygenation characteristics linked to the capillary blood
vessels. Direct extravascular oxygenation of the wound bed was not
determined. A limitation of our ischemia wound model is that it is a
delayedwound healingmodel. Therefore, we are unable to study the
effects of HBOT on healing arrested chronic wounds as observed in
some patients. Nevertheless, the study has its merit as the healing
arrested chronic wounds also may enter the healing phase during
HBOT.Limitationsof our experimental designare thatnon-diabetic
controlanimalsare lackingandthatperfusionmeasurementsonlyare
taken 20 hours after the last hyperbaric treatment. Therefore, it is
unknown if the observedHBOTeffects on tissue perfusion are due to
the entire course of treatments or only to the last treatment.
In our study we complied the clinical HBOT protocol
recommendation consisting of treatments on 20–40 workings days
during 90–120 minutes at a pressure of 2.4 atmospheres absolute.
A deviation from this protocol, however, is that humans normally
are placed in a pressurized air chamber and breathe pure oxygen
through a mask for 20–30 minutes, alternated by a short period of
normoxia. This approach is considered to limit the toxic side
effects of hyperoxia [15]. As our animals do not tolerate breathing
through a mask, the HBO chamber that was used for this study is
completely filled with pressurized pure oxygen. Thereby omitting
the normoxia periods. To our knowledge, effects of these
normoxia periods on the effectiveness of HBOT in improving
wound healing are not described in literature.
In summary, we observe a lasting improved tissue oxygenation
by HBOT in our diabetic rat wound model. Effects on improving
the breaking strength and the healing of the wounded skin are in
need of further research.
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